# WJB001

Source: https://onco.cc/drugs/wjb001/  
OnCo record `wjb001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

WJB001 is a small-molecule inhibitor from Wigen Biomedicine Technology (Shanghai) Co., Ltd., in registered phase 2 trials for metastatic cancer.

## Summary

WJB001 is listed on ClinicalTrials.gov as an intervention in 8 registered phase 2 trials sponsored by Wigen Biomedicine Technology (Shanghai) Co., Ltd., in metastatic cancer. Described in the registry record as a wee1 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: Wee1 inhibitor+ Taxol/Abraxane; Wee1 inhibitor+ PARAPLATIN/Aqupla; Wee1 inhibitor+ PARAPLATIN+Taxol; Wee1 inhibitor+ Zejula
- Tags: pipeline; ctgov-ingest; registry-only
- Code: WJB001
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a wee1 inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of WJB001: https://clinicaltrials.gov/search?intr=WJB001

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- trials: [A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors](https://onco.cc/trials/nct06953323/), [A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05773820/)

---
JSON: https://onco.cc/api/v1/entities/wjb001.json